FINWIRES · TerminalLIVE
FINWIRES

Lotte Chemical Titan Incurs Wider Loss Despite 70% Higher Revenue

By

-- Lotte Chemical Titan (KLSE:LCTITAN) posted a wider first-quarter loss despite a 70% jump in revenue, according to a Thursday Malaysian bourse filing.

Shares slid over 1% in Friday's midday trade.

The loss widened as higher depreciation and financing costs from its Indonesia ethylene project weighed on earnings.

Loss before tax rose to 230 million ringgit from 135 million ringgit a year earlier, even as revenue climbed to 2.53 billion ringgit from 1.49 billion ringgit.

The higher revenue was driven by higher sales volumes from the Indonesia New Ethylene project that began commercial operations in October 2025.

The group reported EBITDA of 150 million ringgit, compared with a negative EBITDA of 38 million ringgit a year earlier, while plant utilization improved to 61% from 46%.

Lotte Chemical Titan said ongoing geopolitical tensions in the Middle East, particularly the Iran war, continue to create uncertainty in the global petrochemical market.

Related Articles

Asia

Apollo Micro Systems Clinches Orders Worth INR510 Million; Shares Up 4%

Defense manufacturer Apollo Micro Systems (NSE:APOLLO, BOM:540879) has secured new orders worth a total of 510.3 million Indian rupees, according to a Friday filing to the Indian stock exchanges.Of the total, orders of 174.8 million rupees from the Ministry of Defence, Government of India, contracts of 95.3 million rupees from public sector defense undertakings, and orders worth 240.2 million rupees from private companies.The company's shares were up nearly 4% in recent trade.

$BOM:540879$NSE:APOLLO
Asia

PKU HealthCare Gets Nod for Tofacitinib Citrate's Marketing

PKU HealthCare (SHE:000788) obtained approval from China's National Medical Products Administration for the marketing of Tofacitinib Citrate, according to a Shenzhen bourse filing on Friday.The drug is a potent Janus kinase (JAK) inhibitor, primarily used for patients suffering from chronic autoimmune conditions, including ankylosing spondylitis, rheumatoid arthritis and psoriatic arthritis.The healthcare company's share rose 1% during the afternoon trade.

$SHE:000788
Asia

Toyota Expects Lower Fiscal 2027 Profit Amid Tariff, Cost Pressures

Toyota Motor (TYO:7203) forecasts weaker profit for fiscal 2027 as rising material and energy costs linked to Middle East tensions are expected to weigh on earnings, according to a Friday filing on the Tokyo Stock Exchange.The automaker expects net income attributable to shareholders to decline 22% to 3 trillion yen in the year ending March 2027, with basic earnings per share projected at 251.25 yen. Revenue is expected to rise slightly to 51 trillion yen.For the fiscal year ended March 2026, Toyota reported net profit attributable to shareholders of 3.848 trillion yen, down 19% from a year earlier, while revenue rose 5.5% to 50.7 trillion yen. Earnings per share fell to 295.25 yen from 359.56 yen a year earlier.The company raised its annual dividend to 95 yen per share from 90 yen and forecast a payout of 100 yen for fiscal 2027.

$TYO:7203